144 related articles for article (PubMed ID: 17242921)
1. Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Zilles K; Bauer A
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1061-70. PubMed ID: 17242921
[TBL] [Abstract][Full Text] [Related]
2. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion.
Bauer A; Langen KJ; Bidmon H; Holschbach MH; Weber S; Olsson RA; Coenen HH; Zilles K
J Nucl Med; 2005 Mar; 46(3):450-4. PubMed ID: 15750158
[TBL] [Abstract][Full Text] [Related]
3. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments.
Elmenhorst D; Kroll T; Wedekind F; Weisshaupt A; Beer S; Bauer A
J Nucl Med; 2013 Aug; 54(8):1411-9. PubMed ID: 23740103
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography.
Kroll T; Elmenhorst D; Weisshaupt A; Beer S; Bauer A
Mol Imaging Biol; 2014 Oct; 16(5):699-709. PubMed ID: 24595700
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET.
Bauer A; Holschbach MH; Cremer M; Weber S; Boy C; Shah NJ; Olsson RA; Halling H; Coenen HH; Zilles K
J Nucl Med; 2003 Oct; 44(10):1682-9. PubMed ID: 14530487
[TBL] [Abstract][Full Text] [Related]
6. 18F-CPFPX PET: on the generation of parametric images and the effect of scan duration.
Meyer PT; Elmenhorst D; Matusch A; Winz O; Zilles K; Bauer A
J Nucl Med; 2006 Feb; 47(2):200-7. PubMed ID: 16455624
[TBL] [Abstract][Full Text] [Related]
7. Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: analyses based on venous blood sampling.
Meyer PT; Elmenhorst D; Zilles K; Bauer A
Synapse; 2005 Mar; 55(4):212-23. PubMed ID: 15668990
[TBL] [Abstract][Full Text] [Related]
8. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach.
Meyer PT; Elmenhorst D; Bier D; Holschbach MH; Matusch A; Coenen HH; Zilles K; Bauer A
Neuroimage; 2005 Feb; 24(4):1192-204. PubMed ID: 15670697
[TBL] [Abstract][Full Text] [Related]
9. A1 adenosine receptor PET using [18F]CPFPX: displacement studies in humans.
Meyer PT; Elmenhorst D; Matusch A; Winz O; Zilles K; Bauer A
Neuroimage; 2006 Sep; 32(3):1100-5. PubMed ID: 16806981
[TBL] [Abstract][Full Text] [Related]
10. Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans.
Meyer PT; Elmenhorst D; Boy C; Winz O; Matusch A; Zilles K; Bauer A
Neurobiol Aging; 2007 Dec; 28(12):1914-24. PubMed ID: 16996650
[TBL] [Abstract][Full Text] [Related]
11. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET.
Meyer PT; Bier D; Holschbach MH; Boy C; Olsson RA; Coenen HH; Zilles K; Bauer A
J Cereb Blood Flow Metab; 2004 Mar; 24(3):323-33. PubMed ID: 15091113
[TBL] [Abstract][Full Text] [Related]
12. Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18F-CPFPX and PET.
Elmenhorst D; Meyer PT; Matusch A; Winz OH; Bauer A
J Nucl Med; 2012 Nov; 53(11):1723-9. PubMed ID: 22966134
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method.
Kim JS; Ichise M; Sangare J; Innis RB
J Nucl Med; 2006 Feb; 47(2):208-14. PubMed ID: 16455625
[TBL] [Abstract][Full Text] [Related]
14. New potent A
Kreft S; Bier D; Holschbach MH; Schulze A; Coenen HH
Nucl Med Biol; 2017 Jan; 44():69-77. PubMed ID: 27821347
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies.
Matusch A; Meyer PT; Bier D; Holschbach MH; Woitalla D; Elmenhorst D; Winz OH; Zilles K; Bauer A
Nucl Med Biol; 2006 Oct; 33(7):891-8. PubMed ID: 17045169
[TBL] [Abstract][Full Text] [Related]
16. Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis.
Boy C; Meyer PT; Kircheis G; Holschbach MH; Herzog H; Elmenhorst D; Kaiser HJ; Coenen HH; Haussinger D; Zilles K; Bauer A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):589-97. PubMed ID: 18000666
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine.
Kimura Y; Ishii K; Fukumitsu N; Oda K; Sasaki T; Kawamura K; Ishiwata K
Nucl Med Biol; 2004 Nov; 31(8):975-81. PubMed ID: 15607479
[TBL] [Abstract][Full Text] [Related]
18. Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [11C]MPDX.
Fukumitsu N; Ishii K; Kimura Y; Oda K; Sasaki T; Mori Y; Ishiwata K
Ann Nucl Med; 2003 Sep; 17(6):511-5. PubMed ID: 14575390
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A(1) receptors in human brain and transfected CHO cells: Inhibition of [(3)H]CPFPX binding by adenosine and caffeine.
Elmenhorst D; Garibotto V; Prescher A; Bauer A
Neurosci Lett; 2011 Jan; 487(3):415-20. PubMed ID: 21056087
[TBL] [Abstract][Full Text] [Related]
20. Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A
Schneider D; Oskamp A; Holschbach M; Neumaier B; Bier D; Bauer A
Nucl Med Biol; 2020; 82-83():1-8. PubMed ID: 31838339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
